🔗 Share this article

Given that the United States proceeds with historic adjustments to its immunization recommendations, a particular individual has surfaced in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by casting doubt on Covid shots in the pandemic and has zeroed in on alleged fatalities after COVID-19 immunization in her recent tenure at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Immunization Schedule

Health officials had intended to announce radical changes to the childhood vaccination calendar earlier this month, synchronizing the US with Denmark’s national calendar, sources say – a major change that would put the US at odds with a large portion of the world with little proof for improved outcomes. The planned update has been postponed until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to speak at the gathering. She was newly appointed acting director of the FDA’s CDER, the fifth appointee to run the division this year.

Consolidating Power at the Regulatory Body

This interim role could signify a strengthened alliance between the pharmaceutical and biologics centers as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for halting specific childhood shot schedules in the US so as to align more in line with the Danish model, a nation with nationalized medicine and a population roughly the size of Wisconsin’s.

In her initial statements, she has kept her attention on immunizations – typically the responsibility of Prasad, chief of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Qualifications

The appointee has no apparent experience in medication creation, approval processes or leadership, which has been customary for past directors of the biologics center. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“It seems she lacks to have the necessary background” for leading the drug-regulation department, remarked Jonathan Howard. “She has not conducted a scientific study. She lacks experience in leading a large organization. She has no expertise in drug approvals.”

Past directors of the center would “understand legal statutes and the science of medication creation”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who headed CBER have had.”

This division has an enormous workload at the agency, the former commissioner stated.

“Many people just pays attention on the new drug program, but the generic drug division clears thousands of generic drugs. There is also a biologic copycat branch, OTC medication office and so forth, and every single one have to be supervised,” Woodcock noted. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant administrative aspect to the position, which oversees more than 5,000 staff members. “It’s a huge management job, if you do it right,” the former official added.

Official Statement and Controversial Policies

In response to concerns about Høeg’s qualifications and whether this selection represents greater collaboration among agency officials on immunizations, a press secretary said that the “questions are based on incorrect assumptions”.

“Her resume is consistent with the responsibilities of her role,” the official stated, noting the time Dr. Høeg spent guiding the FDA commissioner on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg takes over the agency head's new fast-track approval initiative, a disputed expedited drug-approval program that apparently concerned her former heads. “By what process are these drugs being chosen for this voucher program? Who takes the calls?” Dr. Howard questioned. “There’s a lot of confidentiality going on at the agency right now.”

Overall, he remarked, “the Food and Drug Administration appears to be shifting towards laxer regulations of all drugs, except for vaccines.”

Established Past Work on Immunizations

Concerning vaccines, Høeg has a more established, if problematic, history, some experts observe. She released a study using non-validated volunteer-provided data to estimate the rate of heart inflammation after Covid vaccination. She advised the Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Included in her “desired changes” for the new federal leadership included altering guidelines for new vaccines and ending “unnecessary” vaccines, she remarked after the election on a online show. At the FDA, Dr. Høeg has allegedly proposed excluding teenage boys from obtaining COVID-19 vaccinations.

“She’s an thorough true believer who commences with her beliefs and works backwards to accommodate the evidence in a extremely disingenuous, fraudulent way,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg became part of fellow skeptics, {like|